Who are F-18-Fluorocholine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PET Scan with [11C]ABP688, [11C]raclopride, [F-18]-Fludeoxyglucose, Raclopride C11, [Ga-68]PSMA, C-11 labeled nicotine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/f-18-fluorocholine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

F-18-Fluorocholine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

F-18-Fluorocholine (F-18-Fluorocholine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent. Area: Oncology.

phase 3 PET imaging agent Choline transporters; Choline kinase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

F-18-Fluorocholine (F-18-Fluorocholine) — ABX advanced biochemical compounds GmbH. F-18-Fluorocholine is a positron emission tomography (PET) imaging agent that accumulates in cells with high choline metabolism, enabling visualization of metabolically active tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
F-18-Fluorocholine TARGET	F-18-Fluorocholine	ABX advanced biochemical compounds GmbH	phase 3	PET imaging agent	Choline transporters; Choline kinase
PET Scan with [11C]ABP688	PET Scan with [11C]ABP688	Stony Brook University	marketed	PET imaging agent / Radiotracer	mGluR5 (metabotropic glutamate receptor 5)
[11C]raclopride	[11C]raclopride	New York State Psychiatric Institute	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
[F-18]-Fludeoxyglucose	[F-18]-Fludeoxyglucose	University of Saskatchewan	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
Raclopride C11	Raclopride C11	University of North Carolina, Chapel Hill	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
C-11 labeled nicotine	C-11 labeled nicotine	University of Cincinnati	marketed	PET imaging agent / radiotracer	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent class)

University of California, San Francisco · 2 drugs in this class
Central Hospital, Nancy, France · 1 drug in this class
Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Institute for Neurodegenerative Disorders · 1 drug in this class
OHSU Knight Cancer Institute · 1 drug in this class
Piramal Imaging Limited · 1 drug in this class
SOFIE · 1 drug in this class
Universidad Central del Caribe · 1 drug in this class
University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). F-18-Fluorocholine — Competitive Intelligence Brief. https://druglandscape.com/ci/f-18-fluorocholine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing